ClinicalTrials.gg
Sign In

Neuralgia, Postherpetic clinical trials

The registry lists 196 studies for Neuralgia, Postherpetic across more than 10 countries. 28 are recruiting or about to start. 144 of them are mainly about Neuralgia, Postherpetic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.

Get an email when these change. Save the Neuralgia, Postherpetic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
129
Recruiting
18
Status unknown
16
Terminated
16
Not yet recruiting
9
Withdrawn
4

Phase

Phase 2
68
Phase 3
26
Phase 4
19
Phase 1
14
Early Phase 1
1

Where

United States
60
China
30
Germany
20
Korea, Republic of
14
United Kingdom
12
Poland
11

Who runs them

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (8) · Pfizer (7) · NeurogesX (5) · Merck Sharp & Dohme LLC (5) · Seoul National University (5) · Beijing Tiantan Hospital (4) · University of California, San Francisco (4) · UCB Pharma (4)

What is being tested here

Drugs under test in Neuralgia, Postherpetic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pregabalin3515
Lacosamide103
Esketamine102
Riluzole101
HL-1186101
Platelet rich plasma101
Capsaicin027
Lidocaine025
Gabapentin035
Botulinum toxin type A004

Drug classes tested here Local anesthetics 6 · Opioids 6 · NSAIDs 3

Coming up

1phase 3 study under way
6studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (11%) take healthy volunteers.

Recruiting studies that take each age, of 18
AgeWomenMen
100 (0%)0 (0%)
1813 (72%)13 (72%)
3016 (89%)16 (89%)
4017 (94%)17 (94%)
5018 (100%)18 (100%)
6517 (94%)17 (94%)
7516 (89%)16 (89%)
8510 (56%)10 (56%)

Across all 196 studies, recruiting or not: 12% stop at 75 or younger and 4% at 65; 2% take children; 0% are for women only and 2% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neuralgia, Postherpetic studies take

Of 12 phase 2 interventional studies under Neuralgia, Postherpetic, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 212 mo9–17 · 12 studies——
Interventional, no phase16 mo10–35 · 32 studies—16 mo10–35 · 30 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Results posted1

Studies

Recruiting first, then most recently updated. Showing 50 of 196. Browse all 196 → or search them.